ESR1 and breast cancer: Since breast cancers are driven by the aberrant hormone-dependent pathways, the hypothesis that loss of estrogen receptor (ER) function results in trans-differentiation from an epithelial to a mesenchymal phenotype, with increased aggressiveness and metastatic potential, has been explored by several authors in recent years [9].